 The FDA has approved BioMarin Pharmaceutical Incs NASDAQ: BMRN Voxzogo vosoritide for Injection for achondroplasia. The approval comes for achondroplasia patients five years and older to increase linear growth in patients with open epiphyses growth plates. 